Stockscreener 앱 받기
10.78
5.69%
-0.65
시간 외 거래:
10.82
0.04
+0.37%
전일 마감가:
$11.43
열려 있는:
$11.31
하루 거래량:
2.42M
Relative Volume:
1.17
시가총액:
$1.63B
수익:
$737.54M
순이익/손실:
$-647.68M
주가수익비율:
-1.9012
EPS:
-5.67
순현금흐름:
$-594.49M
1주 성능:
-10.76%
1개월 성능:
-10.32%
6개월 성능:
+7.69%
1년 성능:
-34.59%
1일 변동 폭
$10.70
$11.40
1주일 범위
$10.70
$11.99
52주 변동 폭
$7.48
$18.57
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.78 | 1.63B | 737.54M | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-06-29 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2026-04-13 | 개시 | Canaccord Genuity | Buy |
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Ono Pharmaceutical (TSE:4528) Secures Biohaven Asia Rights, Is The Stock Still A Bargain? - Simply Wall Street
Ono extends I&I reach in $100M Biohaven deal for IgG degraders - BioWorld News
Biohaven partners with Ono in $100m IgG degrader deal - Pharmaceutical Technology
Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront - BigGo Finance
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement - Benzinga
Biohaven licenses IgG degrader portfolio to Ono for USD 80 million upfront - AllSci
Biohaven signs licensing deal with Japanese drugmaker worth up to $100M - Hartford Business Journal
Biohaven licenses IgG degrader portfolio to Japan’s Ono (BHVN:NYSE) - Seeking Alpha
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease - PR Newswire
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron? - Yahoo Finance
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development - GlobeNewswire Inc.
Roche’s AI lab; Biohaven’s pivotal pause - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Singapore
Biohaven’s cancer drug data selected for presentation at symposium - Investing.com
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - PR Newswire
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced? - Yahoo Finance
Yale, Biohaven Seek $23M Atty Fee After Trade Secrets Win - Law360
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 49.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap - simplywall.st
Biohaven (NYSE:BHVN)Stock Analysis - Simply Wall Street
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
Biohaven (BHVN) discloses options tied to SVP's son - Stock Titan
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven Faces New Securities Investigation - stl.news
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
Why Is Biohaven (NYSE:BHVN) Opakalim Under FDA Hold on NYSE Composite? - Kalkine Media
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
Biohaven’s epilepsy drug hit with FDA clinical hold - Yahoo Finance
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold By Investing.com - Investing.com South Africa
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Biohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trials - finance.biggo.com
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - AllSci
Why is Biohaven Pharmaceutical stock sliding today? - investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Nigeria
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com South Africa
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Canada
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com India
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Yahoo Finance
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Yahoo Finance
FDA places partial hold on Biohaven’s epilepsy drug - Yahoo Finance
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Nigeria
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오헤이븐 주식 (BHVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Buten Matthew | Chief Financial Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,250 |
0 |
198,246 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
14,250 |
0 |
1,811,398 |
| Car Bruce | Chief Scientific Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,750 |
0 |
10,096 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
68,095 |
| Clark George C. | VP, Chief Accounting Officer |
Nov 17 '25 |
Buy |
8.52 |
17,000 |
144,770 |
20,000 |
| Bailey Gregory | Director |
Nov 13 '25 |
Buy |
7.50 |
400,000 |
3,000,000 |
2,020,071 |
| CHILDS JOHN W | Director |
Nov 13 '25 |
Buy |
7.50 |
3,333,333 |
24,999,998 |
5,653,904 |
| Coric Vlad | Chief Executive Officer |
Nov 13 '25 |
Buy |
7.50 |
666,666 |
4,999,995 |
1,195,275 |
2.20%
0.71%
자본화:
|
볼륨(24시간):